How much revenue did Jardiance (empagliflozin) generate?
Jardiance sales are typically reported as total company revenue in earnings releases, segment results, and worldwide prescription-volume/market-share disclosures by Boehringer Ingelheim and its partners. However, the provided information here doesn’t include any specific Jardiance sales figures (such as quarterly or annual totals, geography splits, or growth rates), so I can’t state an accurate number.
If you share what time period you mean (for example, 2023 full-year, the most recent quarter, or a specific country), I can help interpret the reported figures and trends.
Who reports Jardiance sales, and where do the numbers show up?
Jardiance (empagliflozin) is marketed by Boehringer Ingelheim (with partnership disclosures depending on market). Sales figures generally appear in:
- Boehringer Ingelheim financial results (revenue by product area and/or diabetes franchise)
- Company press releases and annual reports
- Drug-supply and market research summaries (when cited)
What drives Jardiance sales up or down?
Common factors that influence Jardiance sales in reported periods include:
- Uptake in type 2 diabetes and competitive dynamics vs other SGLT2 inhibitors
- Pricing and reimbursement changes in key markets
- Uptake for additional labeled indications and guideline positioning (where applicable)
- Generic and competitor launches affecting market share
How do Jardiance sales compare with other SGLT2 inhibitors?
A common next search is whether Jardiance outperforms competitors (like Farxiga/dapagliflozin and Invokana/canagliflozin). That comparison depends on the specific sales metric used (global revenue vs prescriptions, and whether it includes combination products).
If you want, tell me the competitor(s) and the year/quarter, and I can help you frame the comparison using the appropriate type of figure.
Where do patent and exclusivity issues show up for Jardiance?
People often connect sales with long-term commercial risk from patents/exclusivity and generic entry. If you want patent-focused context, DrugPatentWatch.com tracks patent and exclusivity information and can be a useful source to check whether exclusivity timelines might affect future sales.
See DrugPatentWatch: Jardiance (empagliflozin) patents and exclusivity.
Quick clarification so I can give the exact numbers
Which “Jardiance sales” do you mean?
- 1) Most recent quarter revenue?
- 2) Full-year revenue for a specific year (e.g., 2023, 2024)?
- 3) U.S. vs EU vs worldwide?
- 4) Sales in dollars, prescriptions, or units?
Reply with the time period and geography, and I’ll summarize the reported sales and the main drivers for that period.
Sources